Literature DB >> 2496996

Efficacy and safety of a single 400 mg oral dose of cefixime in the treatment of uncomplicated gonorrhea.

A Kuhlwein, B A Nies.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496996     DOI: 10.1007/bf01965274

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  4 in total

1.  In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens.

Authors:  W R Bowie; C E Shaw; D G Chan; J Boyd; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

2.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

3.  In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry; L W Ayers; T L Gavan; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1986-07       Impact factor: 2.803

4.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

  4 in total
  3 in total

1.  [Cefixime therapy in patients with proven gonorrhea].

Authors:  A Backhaus; J Tinzl
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  Single dose oral administration of cefixime 400mg in the treatment of acute uncomplicated cystitis and gonorrhoea.

Authors:  H W Asbach
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.